Premium
Glyceryl‐1‐nitrate pharmacokinetics in healthy volunteers.
Author(s) -
Laufen H,
Leitold M
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03047.x
Subject(s) - pharmacokinetics , bioavailability , volume of distribution , oral administration , urine , chemistry , metabolite , pharmacology , excretion , renal physiology , distribution volume , medicine , renal function , biochemistry
The plasma kinetics and urinary excretion of glyceryl‐1‐nitrate (G‐1‐ N), a metabolite of glyceryl trinitrate with antianginal potential, were investigated in 10 healthy male volunteers, after intravenous infusion and oral administration of 20 mg G‐1‐N. The apparent volume of G‐1‐N distribution was 601 corresponding to 0.761 kg‐1 body weight, on average. It is suggested that total body water is the principal biological correlate of the hydrophilic drug. Mean intravenous clearance was 283 ml min‐1 or 3.61 ml min‐1 kg‐1. The average of elimination half‐lives were 2.50 +/‐ 0.36 (s.d.) h after the intravenous and 2.54 +/‐ 0.40 (s.d.) h after the oral dose. Inter‐ subject variances of pharmacokinetic parameters were low compared to variances reported for glyceryl trinitrate. The coefficient of intra‐ subject variation of the elimination half‐lives was 8.8%. 5.5% (i.v.) and 5.4% (p.o.) of the administered dose were excreted into urine up to 48 h after the administration. 1% (i.v.) and 1.5% (p.o.) were in the conjugated form. The oral dose was rapidly and almost completely absorbed. The oral bioavailability on the basis of areas under the curve amounted to 88.6% on the average. For clinical use, owing to its high oral bioavailability, long residence in the body, inactivation by metabolic conversion, and good predictability of kinetic parameters, G‐ 1‐N offers advantage over glyceryl trinitrate.